The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments
- Author
- Veerle Kersemans, Valentijn Vergote (UGent) , Virginie de Gelder (UGent) , Indira Madani (UGent) , Hubert Thierens (UGent) , Wilfried De Neve (UGent) , J MERTENS, Guido Slegers (UGent) , Christian Burvenich (UGent) , Kathelijne Peremans (UGent) and Bart De Spiegeleer (UGent)
- Organization
-
- Department of Radiation oncology and experimental cancer research (ceased 1-10-2018)
- Department of Pharmaceutical analysis
- Department of Basic Medical Sciences (ceased 1-10-2018)
- Department of Comparative physiology and biometrics
- Department of Veterinary medical imaging and small animal orthopaedics (ceased 1-1-2022)
- Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition
- Abstract
- This study was performed to determine whether [ I-123]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase. Methods: In vitro, uptake of [I-125]-2-iodo-L-phenylalanine in RIM cells was tested after irradiation with Co-60 gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [I-123]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups. Results: The in vitro tests demonstrated that the [I-125]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [I-123]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the tumor-irradiated group, as compared to the contralateral-irradiated group and the not-irradiated control group. Conclusions: These findings in our cell and animal model systems indicate that [I-123]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy.
- Keywords
- BIODISTRIBUTION, CARCINOMA, POTENTIAL TUMOR TRACER, RECURRENT BRAIN-TUMOR, RADIATION NECROSIS, SPECT, PET, THERAPY, DIAGNOSIS, POSITRON-EMISSION-TOMOGRAPHY, bystander effect, radiotherapy response, I-123]-2-iodo-L-phenylalanine, radiolabeled amino acids, tumor imaging
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 121.72 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-416532
- MLA
- Kersemans, Veerle, et al. “The Use of [I-123]-2-Iodo-L-Phenylalanine as an Early Radiotherapy Evaluation Tool: In Vitro R1M Rabdomyosarcoma Cell and in Vivo Mouse Experiments.” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 23, no. 2, 2008, pp. 192–201, doi:10.1089/cbr.2007.0362.
- APA
- Kersemans, V., Vergote, V., de Gelder, V., Madani, I., Thierens, H., De Neve, W., … De Spiegeleer, B. (2008). The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 23(2), 192–201. https://doi.org/10.1089/cbr.2007.0362
- Chicago author-date
- Kersemans, Veerle, Valentijn Vergote, Virginie de Gelder, Indira Madani, Hubert Thierens, Wilfried De Neve, J MERTENS, et al. 2008. “The Use of [I-123]-2-Iodo-L-Phenylalanine as an Early Radiotherapy Evaluation Tool: In Vitro R1M Rabdomyosarcoma Cell and in Vivo Mouse Experiments.” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 23 (2): 192–201. https://doi.org/10.1089/cbr.2007.0362.
- Chicago author-date (all authors)
- Kersemans, Veerle, Valentijn Vergote, Virginie de Gelder, Indira Madani, Hubert Thierens, Wilfried De Neve, J MERTENS, Guido Slegers, Christian Burvenich, Kathelijne Peremans, and Bart De Spiegeleer. 2008. “The Use of [I-123]-2-Iodo-L-Phenylalanine as an Early Radiotherapy Evaluation Tool: In Vitro R1M Rabdomyosarcoma Cell and in Vivo Mouse Experiments.” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 23 (2): 192–201. doi:10.1089/cbr.2007.0362.
- Vancouver
- 1.Kersemans V, Vergote V, de Gelder V, Madani I, Thierens H, De Neve W, et al. The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2008;23(2):192–201.
- IEEE
- [1]V. Kersemans et al., “The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments,” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 23, no. 2, pp. 192–201, 2008.
@article{416532, abstract = {{This study was performed to determine whether [ I-123]-2-iodo-L-phenylalanine single-photon emission computed tomography (SPECT) can be used to monitor the tumor response to radiotherapy in an early phase. Methods: In vitro, uptake of [I-125]-2-iodo-L-phenylalanine in RIM cells was tested after irradiation with Co-60 gamma rays. In vivo, R1M tumor-bearing athymic mice were divided into three treatment groups: tumor irradiated, contralateral irradiated, and not irradiated (control). [I-123]-2-iodo-L-phenylalanine tracer uptake in tumor tissue, contralateral tissue, and front-leg tissue was investigated after various postirradiation time intervals by means of static planar imaging in each of the three treatment groups. Results: The in vitro tests demonstrated that the [I-125]-2-iodo-L-phenylalanine tracer uptake was higher in the remaining cells surviving a high radiation dose, compared to lower and nonradiated cells. In vivo, [I-123]-2-iodo-L-phenylalanine showed neither accumulation in the contralateral tissue nor in the front-leg tissue in each of the three treatment groups. Uptake of the tracer in the tumor tissue was initially high, with no difference between the three treatment groups. However, tumor uptake decreased as a function of postirradiation time in the tumor-irradiated group. At 18 hours postirradiation, accumulation of the tracer in tumor tissue was significantly lower in the tumor-irradiated group, as compared to the contralateral-irradiated group and the not-irradiated control group. Conclusions: These findings in our cell and animal model systems indicate that [I-123]-2-iodo-L-phenylalanine is a suitable tumor SPECT tracer candidate to evaluate and predict the individual patient response to radiotherapy.}}, author = {{Kersemans, Veerle and Vergote, Valentijn and de Gelder, Virginie and Madani, Indira and Thierens, Hubert and De Neve, Wilfried and MERTENS, J and Slegers, Guido and Burvenich, Christian and Peremans, Kathelijne and De Spiegeleer, Bart}}, issn = {{1084-9785}}, journal = {{CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS}}, keywords = {{BIODISTRIBUTION,CARCINOMA,POTENTIAL TUMOR TRACER,RECURRENT BRAIN-TUMOR,RADIATION NECROSIS,SPECT,PET,THERAPY,DIAGNOSIS,POSITRON-EMISSION-TOMOGRAPHY,bystander effect,radiotherapy response,I-123]-2-iodo-L-phenylalanine,radiolabeled amino acids,tumor imaging}}, language = {{eng}}, number = {{2}}, pages = {{192--201}}, title = {{The use of [I-123]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: In vitro R1M rabdomyosarcoma cell and in vivo mouse experiments}}, url = {{http://doi.org/10.1089/cbr.2007.0362}}, volume = {{23}}, year = {{2008}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: